Page 10 - Communications Dept News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Looking Toward Strengthening our Existing Businesses and Creating of New, Highly Profitable Businesses Restructuring Hitachi High-Tech Fine Systems

TOKYO, Feb 2, 2022 - (JCN Newswire) - Hitachi High-Tech Corporation ("Hitachi High-Tech") today announced the restructuring of Hitachi High-Tech Fine Systems Corporation ("HFS") on April 1, 2022, as part

Analytical medical solutionsTech solutions corporationLaboratory solutionsHitachi ltdTech groupTech manufacturing service co ltdTech corporation hitachi highCorporate communications deptIndustrial solutionsTech fine systems corporationNano technology solutionsRailroad inspectionTech corporationHigh tech corporationHitachi high tech fine systems corporationHitachi high tech

acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.

Tech solutions corporationAnalytical medical solutionsLaboratory solutionsHitachi ltdTech groupTech manufacturing service co ltdTech corporation hitachi highCorporate communications deptIndustrial solutionsNano technology solutionsTech fine systems corporationRailroad inspectionTech corporationToward strengtheningExisting businessesHigh tech corporation

Nippon Shinyaku and Capricor Therapeutics Enter into an Exclusive Partnership for Commercialization and Distribution of CAP-1002 for the Treatment* of Duchenne Muscular Dystrophy in US

/PRNewswire/ NS Pharma Note: CAP-1002 is an investigational therapy and not approved in the US. This press release is being provided for a US audience as a.

United statesNew jerseyLinda marbTsugio tanakaToru nakaiNs pharma incCapricor therapeutics incNippon shinyaku co ltdDrug administrationCorporate communications deptNippon shinyakuCapricor therapeuticsOrphan drug designationRegenerative medicine advanced therapyCentury treatment actCentury cures act

Nippon Shinyaku and Capricor Therapeutics Enter into an Exclusive Partnership for Commercialization and Distribution of CAP-1002 for the Treatment* of Duchenne Muscular Dystrophy in US

/PRNewswire/ NS Pharma Note: CAP-1002 is an investigational therapy and not approved in the US. This press release is being provided for a US audience as a.

United statesNew jerseyLinda marbTsugio tanakaToru nakaiNs pharma incCapricor therapeutics incNippon shinyaku co ltdDrug administrationCorporate communications deptNippon shinyakuCapricor therapeuticsOrphan drug designationRegenerative medicine advanced therapyCentury treatment actCentury cures act

Huawei ranked 2nd in EU Industrial R&D Investment Scoreboard – KachTech Media

Huawei ranked 2nd in EU Industrial R&D Investment Scoreboard – KachTech Media
kachwanya.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kachwanya.com Daily Mail and Mail on Sunday newspapers.

Tony jinCatherine chenAlberto onettiEuropean commission startup europe partnershipHuawei mobile servicesEuropean commissionEu joint research centrePublic affairsEuropean commission industrial rd investment scoreboardCommunications dept at huaweiHuawei developer programResearch centreChief representativeCorporate startup starsCorporate startup stars awardsStartup europe partnership